Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[PTH].

Masaru Shimizu1

  • 1Phamaceutical Research Lab. II, Chugai Phamaceutical Co., LTD.

Clinical Calcium
|March 19, 2005
PubMed
Summary
This summary is machine-generated.

Injectable parathyroid hormone (PTH) is a proven bone anabolic agent for osteoporosis. New delivery methods like nasal, transdermal, and oral PTH are in development for future osteoporosis therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Initial Nintedanib Dose and Treatment Continuation in Patients With Connective Tissue Disease-Associated Interstitial Lung Disease: A Retrospective Single-Center Observational Study in Japan.

International journal of rheumatic diseases·2026
Same author

Native Wrist Septic Arthritis due to Corynebacterium striatum after Short-Term Systemic Glucocorticoids.

Internal medicine (Tokyo, Japan)·2026
Same author

Potential role of extracellular vesicles in bacterial phagocytosis during Escherichia coli pneumonia in ex vivo perfused human lungs.

Intensive care medicine experimental·2026
Same author

Possible involvement of eosinophil Etosis in hepatic injury associated with hypereosinophilic syndrome.

Modern rheumatology case reports·2026
Same author

EPPT-CTG regeneration using rhFGF-2/CO<sub>3</sub>Ap for Cemental Tear Defects: A case report.

Clinical advances in periodontics·2026
Same author

Pathogenic role of IFNγ from activated CD4+ T cells in lupus model mice induced by topical treatment with toll-like receptor agonist imiquimod.

Clinical and experimental immunology·2025

Area of Science:

  • Endocrinology and Bone Metabolism
  • Pharmacology and Drug Delivery

Context:

  • Injectable parathyroid hormone (PTH) and its N-terminal fragments are established bone anabolic agents.
  • Randomized clinical trials have confirmed the efficacy of injectable PTH therapies.

Purpose:

  • To review the development of alternative delivery forms of parathyroid hormone (PTH) for osteoporosis treatment.
  • To highlight emerging PTH-based therapies and their potential impact on osteoporosis management.

Summary:

  • Injectable parathyroid hormone (PTH) (1-34) and its fragments are effective bone anabolic agents.
  • Alternative delivery systems, including nasal, transdermal, and pulmonary formulations of PTH (1-34), are under clinical or preclinical investigation.
  • Oral formulations of PTH (1-34) and analogs, as well as orally active calcium-sensing receptor antagonists that stimulate PTH secretion, are also in development.

Related Experiment Videos

Impact:

  • Parathyroid hormone (PTH) is poised to become a cornerstone therapeutic agent for osteoporosis.
  • Advancements in PTH delivery methods promise improved patient compliance and therapeutic outcomes.
  • The development of novel PTH-based treatments offers new hope for effective osteoporosis management.